Background and purpose The best therapeutic approach for aggressive relapsing–remitting
multiple sclerosis remains unknown. The objective was to compare the efficacy and safety of …

Background: The absence of reliable imaging or biological markers of phenotype transition
in multiple sclerosis (MS) makes assignment of current phenotype status difficult. Objective …

The role of microorganism in human diseases cannot be ignored. These microorganisms
have evolved together with humans and worked together with body's mechanism to maintain …

Progressive Multiple Sclerosis : CONTINUUM: Lifelong Learning in Neurology Account
Register Activate Subscription Help Subscribe American Academy of Neurology Login …

Objective: To investigate the effect of disease-modifying treatment on short-term disability
outcomes in secondary progressive multiple sclerosis (SPMS). Methods: Using MSBase, an …

Introduction Patients with progressive multiple sclerosis (PMS) experience relentless
disability worsening. Current approved therapies have very modest effects on disability …

Background and Objectives Histopathologic studies have identified immunoglobulin (Ig)
deposition and complement activation as contributors of CNS tissue damage in multiple …

Background Multiple sclerosis (MS) patients with stable disease course might view
continued treatment as unnecessary. However, guidelines regarding treatment …

Background & Objectives Published natural history data on late-onset of multiple sclerosis
are limited. We aimed to assess the risk of attaining EDSS 6.0 among patients with late …

Objective Currently, 233 genetic loci are known to be associated with susceptibility to
multiple sclerosis (MS). Two independent pivotal severity genome‐wide association studies …